ECSP13012392A - Cristal de compuesto de amida - Google Patents
Cristal de compuesto de amidaInfo
- Publication number
- ECSP13012392A ECSP13012392A ECSP13012392A ECSP13012392A EC SP13012392 A ECSP13012392 A EC SP13012392A EC SP13012392 A ECSP13012392 A EC SP13012392A EC SP13012392 A ECSP13012392 A EC SP13012392A
- Authority
- EC
- Ecuador
- Prior art keywords
- crystal
- amida
- ylcarbonyl
- methoxybutyl
- morpholin
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 3
- 241000670727 Amida Species 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- -1 4-methoxybutyl Chemical group 0.000 abstract 3
- 206010020772 Hypertension Diseases 0.000 abstract 2
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 2
- XIZCDQOKKYYCRH-UHFFFAOYSA-N 1h-benzimidazole-2-carboxamide Chemical compound C1=CC=C2NC(C(=O)N)=NC2=C1 XIZCDQOKKYYCRH-UHFFFAOYSA-N 0.000 abstract 1
- 102100028255 Renin Human genes 0.000 abstract 1
- 108090000783 Renin Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
- 230000004768 organ dysfunction Effects 0.000 abstract 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe un cristal de clorhidrato de 1-(4-metoxibutil)-N-(2-metilpropil)-N-[(3S,5R)-5-(morfolin-4-ilcarbonil)piperidin-3-il]-1H-bencimidazol-2-carboxamida que tiene excelente actividad inhibitoria de renina que es útil como un conservador u otro agente terapéutico para tipos de disfunción de órganos y similares, que se derivan de alta presión sanguínea e hipertensión. El cristal de clorhidrato de 1-(4-metoxibutil)-N-(2-metilpropil)-N-[(3S,5R)-5-(morfolin-4-ilcarbonil)piperidin-3-il]-1H-bencimidazol-2-carboxamida tiene un patrón de difracción de rayos-X de polvo, en donde el espaciamiento de celosía (d) del patrón de difracción de rayos-X de polvo, tiene picos característicos que aparecen en los alrededores de 26.43 ± 0.2, 7.62 ± 0.2 y 4.32 ± 0.2 angstroms.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010137194 | 2010-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP13012392A true ECSP13012392A (es) | 2013-03-28 |
Family
ID=45348277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP13012392 ECSP13012392A (es) | 2010-06-16 | 2013-01-16 | Cristal de compuesto de amida |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9018374B2 (es) |
| EP (1) | EP2583967B1 (es) |
| JP (1) | JP5782438B2 (es) |
| KR (1) | KR20130119903A (es) |
| CN (1) | CN103068816B (es) |
| AU (1) | AU2011266099B2 (es) |
| BR (1) | BR112012032055B8 (es) |
| CA (1) | CA2802483C (es) |
| CL (1) | CL2012003526A1 (es) |
| CO (1) | CO6670573A2 (es) |
| DO (1) | DOP2012000313A (es) |
| EA (1) | EA022094B1 (es) |
| EC (1) | ECSP13012392A (es) |
| ES (1) | ES2524896T3 (es) |
| GE (1) | GEP20146195B (es) |
| IL (1) | IL223562A (es) |
| MA (1) | MA34378B1 (es) |
| MX (1) | MX2012014828A (es) |
| MY (1) | MY163927A (es) |
| PE (1) | PE20130283A1 (es) |
| PH (1) | PH12012502468A1 (es) |
| SG (1) | SG186223A1 (es) |
| TN (1) | TN2012000589A1 (es) |
| TW (1) | TWI511967B (es) |
| UA (1) | UA108888C2 (es) |
| WO (1) | WO2011158880A1 (es) |
| ZA (1) | ZA201300065B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2800734A1 (en) * | 2012-02-14 | 2014-11-12 | Dow Global Technologies LLC | Nonionic surfactant compositions |
| WO2013122260A1 (en) | 2012-02-15 | 2013-08-22 | Takeda Pharmaceutical Company Limited | Tablet |
| CN103831159B (zh) * | 2014-01-20 | 2016-04-13 | 华润赛科药业有限责任公司 | 一种阿齐沙坦微粉化方法 |
| EP3130581A4 (en) * | 2014-04-10 | 2017-11-22 | Takeda Pharmaceutical Company Limited | Method for producing heterocyclic compound |
| GB2542876B (en) * | 2015-04-20 | 2019-10-23 | Johnson Matthey Plc | Structure Directing Agent |
| CN107595853A (zh) * | 2017-10-25 | 2018-01-19 | 桂林浩新科技服务有限公司 | 一种用于治疗高血压合并冠心病的药物组合物及其用途 |
| CN107595842A (zh) * | 2017-10-25 | 2018-01-19 | 桂林浩新科技服务有限公司 | 一种药物复方制剂及在制备治疗高血压合并冠心病的药物中的用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0862562B1 (en) | 1995-09-13 | 2001-07-04 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| EP1302462A4 (en) | 2000-07-17 | 2007-07-18 | Takeda Pharmaceutical | SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF |
| US7342117B2 (en) * | 2001-10-30 | 2008-03-11 | Astellas Pharma Inc. | α-form or β-form crystal of acetanilide derivative |
| AR041867A1 (es) | 2002-11-01 | 2005-06-01 | Takeda Pharmaceutical | Agente para prevenir o tratar neuropatia |
| US7960369B2 (en) | 2002-11-08 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Receptor function regulator |
| CA2507026A1 (en) | 2002-11-22 | 2004-06-10 | Takeda Pharmaceutical Company Limited | Imidazole derivatives, their production and use |
| US20060223831A1 (en) | 2003-04-15 | 2006-10-05 | Isao Kinoyama | Bromide and its crystal |
| JP3618341B2 (ja) * | 2003-04-15 | 2005-02-09 | 山之内製薬株式会社 | 臭化物及びその結晶 |
| EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONDENSED CYCLIC COMPOUND |
| JP2006527770A (ja) | 2003-06-18 | 2006-12-07 | アストラゼネカ アクチボラグ | Ｃｂ１モジュレーターとしての２−置換５，６−ジアリール−ピラジン誘導体 |
| EP1669352A4 (en) | 2003-09-30 | 2008-12-17 | Takeda Pharmaceutical | THIAZOLINE DERIVATIVE AND ITS USE |
| CA2550012A1 (en) | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same and use |
| TW200523247A (en) | 2003-12-25 | 2005-07-16 | Takeda Pharmaceutical | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
| US7585880B2 (en) | 2003-12-26 | 2009-09-08 | Takeda Pharmaceutical Company Limited | Phenylpropanoic acid derivatives |
| US7786165B2 (en) | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
| EP1731505B1 (en) | 2004-03-30 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| WO2006112549A1 (ja) | 2005-04-20 | 2006-10-26 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物 |
| US20090208584A1 (en) | 2005-06-09 | 2009-08-20 | Tomohiro Yoshinari | Solid preparation |
| GB0514203D0 (en) | 2005-07-11 | 2005-08-17 | Novartis Ag | Organic compounds |
| EP1911738A4 (en) | 2005-07-29 | 2009-12-16 | Takeda Pharmaceutical | COMPOUND OF PHENOXYALKANOIC ACID |
| JP5084503B2 (ja) | 2005-07-29 | 2012-11-28 | 武田薬品工業株式会社 | シクロプロパンカルボン酸化合物 |
| EP1912645A2 (en) | 2005-08-10 | 2008-04-23 | Takeda Pharmaceutical Company Limited | Therapeutic agent for diabetes |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| PT2248812E (pt) | 2006-06-27 | 2014-03-12 | Takeda Pharmaceutical | Compostos cíclicos fundidos como moduladores do receptor gpr40 |
| WO2008047821A1 (en) | 2006-10-18 | 2008-04-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| WO2008050821A1 (en) | 2006-10-19 | 2008-05-02 | Takeda Pharmaceutical Company Limited | Indole compound |
| WO2008093639A1 (ja) | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
| AU2008215490A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of PPAR-gamma |
| JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| WO2008156757A1 (en) | 2007-06-19 | 2008-12-24 | Takeda Pharmaceutical Company Limited | Indazole compounds for activating glucokinase |
| JP2010229034A (ja) | 2007-07-26 | 2010-10-14 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピロール誘導体 |
| EP2297114B1 (en) * | 2008-06-19 | 2018-06-06 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| JP4901849B2 (ja) | 2008-12-15 | 2012-03-21 | バブコック日立株式会社 | 空気清浄機、及び分析室、並びに空気の浄化方法 |
| US8642622B2 (en) | 2010-06-16 | 2014-02-04 | Bristol-Myers Squibb Company | Piperidinyl compound as a modulator of chemokine receptor activity |
-
2011
- 2011-06-15 MX MX2012014828A patent/MX2012014828A/es active IP Right Grant
- 2011-06-15 ES ES11795784.5T patent/ES2524896T3/es active Active
- 2011-06-15 MY MYPI2012005311A patent/MY163927A/en unknown
- 2011-06-15 WO PCT/JP2011/063735 patent/WO2011158880A1/ja not_active Ceased
- 2011-06-15 TW TW100120982A patent/TWI511967B/zh not_active IP Right Cessation
- 2011-06-15 CA CA2802483A patent/CA2802483C/en not_active Expired - Fee Related
- 2011-06-15 PH PH1/2012/502468A patent/PH12012502468A1/en unknown
- 2011-06-15 EA EA201291453A patent/EA022094B1/ru not_active IP Right Cessation
- 2011-06-15 EP EP11795784.5A patent/EP2583967B1/en active Active
- 2011-06-15 UA UAA201300523A patent/UA108888C2/ru unknown
- 2011-06-15 GE GEAP201112963A patent/GEP20146195B/en unknown
- 2011-06-15 PE PE2012002427A patent/PE20130283A1/es active IP Right Grant
- 2011-06-15 US US13/704,039 patent/US9018374B2/en not_active Expired - Fee Related
- 2011-06-15 KR KR1020137000759A patent/KR20130119903A/ko not_active Ceased
- 2011-06-15 JP JP2012520480A patent/JP5782438B2/ja not_active Expired - Fee Related
- 2011-06-15 CN CN201180039608.XA patent/CN103068816B/zh not_active Expired - Fee Related
- 2011-06-15 SG SG2012090122A patent/SG186223A1/en unknown
- 2011-06-15 AU AU2011266099A patent/AU2011266099B2/en not_active Ceased
- 2011-06-15 BR BR112012032055A patent/BR112012032055B8/pt not_active IP Right Cessation
- 2011-06-16 MA MA35560A patent/MA34378B1/fr unknown
-
2012
- 2012-12-11 IL IL223562A patent/IL223562A/en active IP Right Grant
- 2012-12-13 TN TNP2012000589A patent/TN2012000589A1/en unknown
- 2012-12-13 CL CL2012003526A patent/CL2012003526A1/es unknown
- 2012-12-14 DO DO2012000313A patent/DOP2012000313A/es unknown
-
2013
- 2013-01-03 ZA ZA2013/00065A patent/ZA201300065B/en unknown
- 2013-01-15 CO CO13006575A patent/CO6670573A2/es unknown
- 2013-01-16 EC ECSP13012392 patent/ECSP13012392A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13012392A (es) | Cristal de compuesto de amida | |
| CL2009000394A1 (es) | Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer. | |
| CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| UY38160A (es) | Partículas implantables y métodos relacionados | |
| MX366949B (es) | Análogos sustituidos de (e)-n'-(1-feniletiliden)benzohidrazida como inhibidores de histona desmetilasa. | |
| BR112012016797A2 (pt) | intensificador dinâmico de baixo utilizando compressor com equalizador incorporado | |
| CL2008003822A1 (es) | Compuestos derivados de n1-(2-tiazolil)-1,2-dicarboxamida pirrolidina; procedimiento de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades mejoradas por la inhibicion de la fosfatidilinositol-3-cinasa, como el cancer. | |
| PE20141824A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| CR20130281A (es) | Compuesto bicíclico | |
| NI200900184A (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer. | |
| UY30107A1 (es) | Nuevos derivados de pirimidina, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones | |
| PE20140040A1 (es) | Composicion farmaceutica que comprende un inhibidor de la actividad de mek | |
| CR10748A (es) | Compuesto de indol | |
| UY31863A (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
| MX2020004491A (es) | Preparacion externa para tratar tinea unguium. | |
| CL2011002650A1 (es) | Composicion que comprende n-(4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il)-2-metilpiridin-5-carboxamida y l-dopa; uso del compuesto para el tratamiento de un trastorno del movimiento secundario de la terapia con l-dopa; uso del compuesto y l-dopa y/o para el tratamiento y/o profilaxis de la enfermedad de parkinson. | |
| MX377172B (es) | Formulacion de combinacion de tesofensina y betabloqueante | |
| PE20170470A1 (es) | Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdidad de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes | |
| MX376496B (es) | Agente protector para queratoconjuntiva o agente supresor para el trastorno queratoconjuntival. | |
| MX2021015853A (es) | Analogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluor-met il)pirimidin-5-il]etil}benzamida. | |
| SV2010003526A (es) | Benzotiazoles como moduladores del receptor de grelina | |
| CO2017005990A2 (es) | Combinaciones de compuestos activos que comprenden (a) una carboxamida de indanilo difluorometil-nicotínico de fórmula (i) y otro compuesto activo como fungicida (b) | |
| CL2011002045A1 (es) | Compuesto derivado de n-[(3e)-5-(cicloalquilamino)-5-oxo-1-fenilpent-3-en-2-il]benzamida, utiles en el tratamiento del prurito de causa desconocido o asociado a una enfermedad dermatologica tal como dermatitis atopica, psoriasis, urticaria, entre otras; combinacion farmaceutica. | |
| PE20190150A1 (es) | 6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORyT | |
| MX2019012967A (es) | Cristal de base libre de derivados benzofurano y metodo de preparacion. |